SEARCH

SEARCH BY CITATION

References

  • Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J., and Pinsky, M.R. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 13031310.
  • Barnes, P.J., and Karin, M. (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 10661071.
  • Bignell, G.R., Warren, W., Seal, S., Takahashi, M., Rapley, E., Barfoot, R., et al. (2000) Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 25: 160165.
  • Bochud, P.Y., and Calandra, T. (2003) Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ 326: 262266.
  • Brummelkamp, T.R., Nijman, S.M., Dirac, A.M., and Bernards, R. (2003) Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424: 797801.
  • Byl, B., Clevenbergh, P., Kentos, A., Jacobs, F., Marchant, A., Vincent, J.L., and Thys, J.P. (2001) Ceftazidime- and imipenem-induced endotoxin release during treatment of gram-negative infections. Eur J Clin Microbiol Infect Dis 20: 804807.
  • Cohen, J. (2002) The immunopathogenesis of sepsis. Nature 420: 885891.
  • Costello, C.M., Mah, N., Hasler, R., Rosenstiel, P., Waetzig, G.H., Hahn, A., et al. (2005) Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med 2: e199.
  • Diekema, D.J., Pfaller, M.A., Jones, R.N., Doern, G.V., Winokur, P.L., Gales, A.C., et al. (1999) Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 29: 595607.
  • Edgeworth, J.D., Treacher, D.F., and Eykyn, S.J. (1999) A 25-year study of nosocomial bacteremia in an adult intensive care unit. Crit Care Med 27: 14211428.
  • Janeway, C.A., Jr, and Medzhitov, R. (2002) Innate immune recognition. Annu Rev Immunol 20: 197216.
  • Jeyaseelan, S., Manzer, R., Young, S.K., Yamamoto, M., Akira, S., Mason, R.J., and Worthen, G.S. (2005) Induction of CXCL5 during inflammation in the rodent lung involves activation of alveolar epithelium. Am J Respir Cell Mol Biol 32: 531539.
  • Jono, H., Lim, J.H., Chen, L.F., Xu, H., Trompouki, E., Pan, Z.K., et al. (2004) NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway. J Biol Chem 279: 3617136174.
  • Karzai, W., Von Specht, B.U., Parent, C., Haberstroh, J., Wollersen, K., Natanson, C., et al. (1999) G-CSF during Escherichia coli versus Staphylococcus aureus pneumonia in rats has fundamentally different and opposite effects. Am J Respir Crit Care Med 159: 13771382.
  • Karzai, W., Cui, X., Mehlhorn, B., Straube, E., Hartung, T., Gerstenberger, E., et al. (2003) Protection with antibody to tumor necrosis factor differs with similarly lethal Escherichia coli versus Staphylococcus aureus pneumonia in rats. Anesthesiology 99: 8189.
  • Kawai, T., Adachi, O., Ogawa, T., Takeda, K., and Akira, S. (1999) Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11: 115122.
  • Kawai, T., Takeuchi, O., Fujita, T., Inoue, J., Muhlradt, P.F., Sato, S., et al. (2001) Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 167: 58875894.
  • Kovalenko, A., Chable-Bessia, C., Cantarella, G., Israel, A., Wallach, D., and Courtois, G. (2003) The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424: 801805.
  • Kurt-Jones, E.A., Chan, M., Zhou, S., Wang, J., Reed, G., Bronson, R., et al. (2004) Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci USA 101: 13151320.
  • Li, Y., Cui, X., Li, X., Solomon, S.B., Danner, R.L., Banks, S.M., et al. (2008) Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model: risk and corticosteroids in sepsis. Intensive Care Med 34: 568577.
  • Lim, J.H., Jono, H., Koga, T., Woo, C.H., Ishinaga, H., Bourne, P., et al. (2007a) Tumor suppressor CYLD acts as a negative regulator for non-typeable Haemophilus influenza-induced inflammation in the middle ear and lung of mice. PLoS ONE 2: e1032.
  • Lim, J.H., Stirling, B., Derry, J., Koga, T., Jono, H., Woo, C.H., et al. (2007b) Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity 27: 349360.
  • Marrie, T.J., Fine, M.J., Obrosky, D.S., Coley, C., Singer, D.E., and Kapoor, W.N. (1998) Community-acquired pneumonia due to Escherichia coli. Clin Microbiol Infect 4: 717723.
  • Martino, R., Santamaria, A., Munoz, L., Pericas, R., Altes, A., Prats, G., and Sierra, J. (1999) Bacteremia by gram-negative bacilli in patients with hematologic malignancies. Comparison of the clinical presentation and outcome of infections by enterobacteria and non-glucose-fermenting gram-negative bacilli. Acta Haematol 102: 711.
  • Mizgerd, J.P., Peschon, J.J., and Doerschuk, C.M. (2000) Roles of tumor necrosis factor receptor signaling during murine Escherichia coli pneumonia. Am J Respir Cell Mol Biol 22: 8591.
  • Ong, E.S., Gao, X.P., Xu, N., Predescu, D., Rahman, A., Broman, M.T., et al. (2003) E. coli pneumonia induces CD18-independent airway neutrophil migration in the absence of increased lung vascular permeability. Am J Physiol Lung Cell Mol Physiol 285: L879L888.
  • Packham, D.R., and Sorrell, T.C. (1981) Pneumonia with bacteraemia due to Escherichia coli. Aust N Z J Med 11: 669672.
  • Pinsky, M.R. (2004) Dysregulation of the immune response in severe sepsis. Am J Med Sci 328: 220229.
  • Reiley, W., Zhang, M., and Sun, S.C. (2004) Negative regulation of JNK signaling by the tumor suppressor CYLD. J Biol Chem 279: 5516155167.
  • Reiley, W.W., Jin, W., Lee, A.J., Wright, A., Wu, X., Tewalt, E.F., et al. (2007) Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J Exp Med 204: 14751485.
  • Sakai, A., Koga, T., Lim, J.H., Jono, H., Harada, K., Szymanski, E., et al. (2007) The bacterium, nontypeable Haemophilus influenzae, enhances host antiviral response by inducing Toll-like receptor 7 expression: evidence for negative regulation of host anti-viral response by CYLD. FEBS J 274: 36553668.
  • Trompouki, E., Hatzivassiliou, E., Tsichritzis, T., Farmer, H., Ashworth, A., and Mosialos, G. (2003) CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424: 793796.
  • Ulevitch, R.J., and Tobias, P.S. (1995) Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 13: 437457.
  • Yoshida, H., Jono, H., Kai, H., and Li, J.D. (2005) The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 and TRAF7. J Biol Chem 280: 4111141121.
  • Zhang, J., Stirling, B., Temmerman, S.T., Ma, C.A., Fuss, I.J., Derry, J.M., and Jain, A. (2006) Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J Clin Invest 116: 30423049.